Doktorgrader og publikasjoner forskningsgruppe Translasjonell kreftforskning
Doktorgrader 2008-2012
Andrej Valkov. Molecular prognostic markers in soft tissue sarcomas. Sept 2012. Primary supervisor: Lill-Tove Busund
Thomas Kilvær. Angiogenic markers as prognostic factors in soft tissue sarcomas. May 2012. Primary supervisor: Tom Dønnem
Sigve Andersen. Hypoxic markers and prognosis in non-small cell lung cancer (NSCLC). Nov 2011. Primary supervisor: Roy M. Bremnes
Khalid Al-Shibli. The prognostic significance of the innate and adaptive immune system in non-small cell lung carcinoma. May 2010. Primary supervisor: Lill-Tove Busund
Samer Al-Saad. Prognostic impact of molecular markers related to tumor differentiation and proliferation in non-small cell lung cancer. April 2010. Primary supervisor: Lill-Tove Busund
Bjørn-Henning Grønberg. Pemetrexed in the treatment of advanced lung cancer. March 2010. Co-supervisor: Roy M. Bremnes
Hege Sagstuen. Cardiovascular risk factors and pulmonary function in long-term survivors of testicular cancer. April 2009. Primary supervisor: Roy M. Bremnes
Tom Dønnem. Molecular analysis of angiogenic markers as prognostic factors for non-small cell lung cancer (NSCLC) – A new translational research strategy involving tissue microarray technology at the University Hospital North Norway and the University of Tromsø. March 2009. Primary supervisor: Roy M. Bremnes
Nina Helbekkmo. Advances non-small cell lung cancer. Effects of chemotherapy and impacts on health related quality of life. March 2009. Primary supervisor: Roy M. Bremnes.
Elin Richardsen. Prognostic molecules in hormone-sentive carcinomas with special focus on prostate cancer. April 2008 Primary supervisor: Lill-Tove Busund
Publikasjoner 2005-2012
2012
Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Bjøro T, Wentzel-Larsen T, Dahl O. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer and association with paternity. Br J Cancer 107(11): 1833-9, 2012
Eilertsen M, Pettersen I, Andersen S, Martinez I, Dønnem T, Busund LT, Bremnes RM. In NSCLC, VEGF-A and VEGF-C response to hypoxia differ between squamous cell and adenocarcinoma histology. Anticancer Res 32(11): 4729-36, 2012
Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland S, Al-Shibli K, Bremnes RM, Busund LT. Prognostic impact of Jab1, p16, p21, p62 and Skp2 in soft tissue sarcomas. PLOS One 7(10): 2012. 10.1371/journal.pone.0047068
Haugnes HS, Bosl G, Boer H, Gietema JA, Brydøy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD. Long-term and late effects of testicular cancer treatment and implications for follow-up. J Clin Oncol 30(30): 3752-63, 2012 Invited review
Dønnem T, Bremnes RM, Busund LT, Andersen S, Pezzella F. Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis 4(2): 212-3, 2012 Invited editorial
Dønnem T, Ervik B, Magnussen K, Andersen S, Pastow D, Andreassen S, Nørstad T, Helbekkmo N, Bremnes RM, Nordøy T. Bridging the distance: a prospective tele-oncology study in Northern Norway. Support Care Cancer 20(9): 2097-103, 2012
Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C. Vinorelbine and Gemcitabine versus vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III study by the Norwegian Lung Cancer Study Group. Br J Cancer 107(3): 442-7, 2012
Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland S, Al-Shibli K, Bremnes RM, Busund LT. Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67, and TGF-beta in soft tissue sarcomas. BMC Clin Pathol 12(1):7, 2012
Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland S, Al-Shibli K, Bremnes RM, Busund LT. High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncoimmunol 1(1): 75-77, 2012
Brustugun OT, Helland Å, Fjellbirkeland L, Jebsen P, Scott H, Ariansen S, Dønnem T, Bremnes R, Berg T, Grønberg BH, Helgeland L. Mutation testing for non-small cell lung cancer. J Norw Med Assoc 132(8): 952-55, 2012
Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes, Paulssen RH, Busund L-T, Bremnes RM, Chalmers A, Martinez-Zubiaurre I. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol 7(1):59, 2012
Kristiansen W, Andreassen KE, Karlsson R, Aschim EL, Bremnes RM, Dahl O, Fosså SD, Klepp O, Langberg CW, Solberg A, Tretli S, Adami HO, Wiklund F, Grotmol T, Haugen TB. Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Hum Reprod. 27(5): 1525-35, 2012
Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland S, Al-Shibli K, Bremnes RM, Busund LT. Prognostic Impact of Peritumoral Lymphocyte Infiltration in Soft Tissue Sarcomas. BMC Clin Pathol 2012 Febr 29:12(5), 1-10
Haugnes HS, Melby B, Larsen KM, Langdal I, Rasi M, Bremnes RM. Assessment of urinary, bowel and sexual function after dose eascalation from 70 to 76 Gy using image-guided radiotherapy in curative treatment of prostate cancer. Scand J Urol Nephrol. 46(2):124-32, 2012
Smeland E, Kilvaer TK, Sorbye S, Valkov A, Andersen S, Bremnes RM, Busund L-T, Dønnem T. Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma. Sarcoma 2012:541650, 2012.
Dønnem T, Fenton CG, Lønvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes RM, Busund LT. MicroRNA signatures in tumor tissues related to angiogenesis in non-small cell lung cancer. PLOs One 7(1): e29671, 2012
Nieder C, Tollali T, Norum J, Pawinski A, Bremnes RM. A population-based study of the pattern of terminal care and hospital death in patients with non-small cell lung cancer. Anticancer Res 32(1): 189-194, 2012
Stenvold H, Dønnem T, Andersen S, Al-Saad S, Al-Shibli-K, Busund-LT, Bremnes-RM. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: Correlation with a favourable clinical outcome. Lung Cancer 75(2):235-41, 2012
Haugnes HS, Laurell A, Stierner U, Bremnes RM, Dahl O, Cavallin-Ståhl E, Cohn-Cedermark G. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer – a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncol 51(2):168-76, 2012
Nieder C, Grosu AL, Mehta MP. Brain metastases research 1990-2010: pattern of citation and systematic review of highly cited articles. ScientificWorldJournal. 2012;2012:721598.
Nieder C, Aandahl G, Dalhaug A. A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate. Case Rep Oncol Med. 2012;2012:537183.
Nieder C. Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. Strahlenther Onkol. 2012 Oct;188(10):865-72.
Norum J, Nieder C. Socioeconomic characteristics and health outcomes in Sami speaking municipalities and a control group in northern Norway. Int J Circumpolar Health. 2012 Aug 20;71:19127.
Nieder C. Ipilimumab in patients with melanoma and brain metastases. Lancet Oncol. 2012 Jul;13(7):e277; author reply e277-8.
Nieder C, Andratschke NH, Geinitz H, Grosu AL. Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries. Med Sci Monit. 2012 Jul;18(7):CR450-5.
Nieder C, Pawinski A, Dalhaug A. Contribution of case reports to glioblastoma research: systematic review and analysis of pattern of citation. Br J Neurosurg. 2012 Dec;26(6):809-12.
Nieder C. [Extrapulmonary small cell carcinomas: influence of radiotherapy on survival]. Strahlenther Onkol. 2012 Mar;188(3):289-90.
Nieder C, Grosu AL, Spanne O, Andratschke NH, Geinitz H. Brain metastases in patients under 50 years of age: retrospective analysis. Clin Exp Metastasis. 2012 Dec;29(8):949-56.
Nieder C. [Radiotherapy and re-irradiation of breast cancer patients with brain metastases: Survival in the trastuzumab era]. Strahlenther Onkol. 2012 Jul;188(7):638-9.
Nieder C, Marienhagen K, Dalhaug A, Norum J. Towards improved prognostic scores predicting survival in patients with brain metastases: a pilot study of serum lactate dehydrogenase levels. ScientificWorldJournal. 2012;2012:609323.
Norum J, Hofvind S, Nieder C, Schnell EA, Broderstad AR. Mammographic screening in Sami speaking municipalities and a control group. Are early outcome measures influenced by ethnicity? Int J Circumpolar Health. 2012 Apr 16;71:1-6.
Nieder C, Andratschke NH, Geinitz H, Grosu AL. Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies. Strahlenther Onkol. 2012 Aug;188(8):692-5.
Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu AL. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):264-70.
Nieder C, Astner ST, Grosu AL. Glioblastoma research 2006-2010: pattern of citation and systematic review of highly cited articles. Clin Neurol Neurosurg. 2012 Nov;114(9):1207-10.
Nieder C, Pawinski A, Dalhaug A. Contribution of case reports to brain metastases research: systematic review and analysis of pattern of citation. PLoS One. 2012;7(3):e34300.
Norum J, Ramsvik A, Tjeldnes K. Brain damage treated with non proven intensive training 2003-2011: a Norwegian cost analysis. Glob J Health Sci. 2012 Oct 10;4(6):179-84.
Norum J, Olsen A, Nybrodahl I, Sørgaard KW. Compulsory and voluntary admission in psychiatric hospitals in northern Norway 2009-2010. A national registry-based analysis. Nord J Psychiatry. 2013 Feb;67(1):47-52.
Norum J, Nieder C. Sami-speaking municipalities and a control group's access to somatic specialist health care (SHC): a retrospective study on general practitioners' referrals. Int J Circumpolar Health. 2012 Mar 19;71:17346.
Størmer J, Norum J, Olsen LR, Eldevik P, Broderstad AR. Health consumption in Sami speaking municipalities and a control group with regard to medical imaging. Int J Circumpolar Health. 2012 Mar 23;71:17620.
Norum J, Bjerke FE, Nybrodahl I, Olsen A. Admission and stay in psychiatric hospitals in northern Norway among Sami and a control group: a registry-based study. Nord J Psychiatry. 2012 Dec;66(6):422-7.
Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes. 2012 Feb 21;5:110.
Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. BMC Cancer. 2012 Dec 22;12(1):616.
Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res. 2012 Aug 14;14(4):R117.
Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res. 2012 Mar 15;14(2):R47.
2011
Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartin E, Blasco A, Del Pozo N, Rosell R, Guijarro R, Galbis J, Sanchez JJ, Camps C. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 6: 286-290, 2011
Valkov A, Sørbye S, Kilvær T, Dønnem T, Smeland E, Bremnes RM, Busund LT. Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas. Int J Oncol 38: 1031-1040, 2011
Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland S, Al-Shibli K, Bremnes RM, Busund LT. Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas. PLoS One 6 (1): e14611, 2011.
Valkov A, Sørbye S, Kilvaer T, Dønnem T, Smeland E, Bremnes RM, Busund LT. The prognostic impact of TGF-β, fascin, NFκB and PKCζ expression in soft tissue sarcomas. PLoS One. 6(3): e17507, 2011.
Tandstad T, Småland R, Solberg A, Bremnes R, Langberg CW, Laurell A, Stierner U, Stahl O, Cavallin-Stahl E, Klepp OH, Dahl O, Cohn-Cedermark G. Management of seminomatous testicular cancer: A binational prospective population-based study from the Swedish Norwegian testicular cancer study group (SWENOTECA). J Clin Oncol 29(6): 719-725, 2011
Dønnem T, Lønvik K, Eklo K, Berg T, Sørby SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM, Busund L-T. Independent and tissue specific prognostic impact of miR-126 in non-small cell lung cancer: Coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011 Jan 24 [Epub ahead of print]
2010
Kilvaer TK, Valkov A, Sorbye S, Donnem T, Smeland E, Bremnes RM, Busund LT. Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival. Sarcoma 2010: 751304. doi:10.1155/2010/751304
Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T. Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One. 2010 Dec 14;5(12):e15368.
Dønnem T, Al-Saad S, Al-Shibli K, Busund L-T, Bremnes RM. Co-expression of PDGF-B and VEGFR-3 strongly correlate with lymph node metastasis and poor survival in non-small cell lung cancer. Ann Oncol 21; 223-231, 2010
Dønnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund L-T, Bremnes RM. Prognostic impact of Notch ligands and receptors in non-small cell lung cancer: co-expression of notch-1 and vascular endothelial growth factor-a predicts poor survival Cancer 116: 5676-5685, 2010
Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer. 2010 Nov 12. [Epub ahead of print]
Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund L-T. The prognostic value of intraepithelial and stromal CD3, CD117 and CD138 positive cells in non-small cell lung carcinoma. APMIS 118:371-82, 2010.
Dønnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund L-T, Bremnes RM. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 116: 4318-4325, 2010
Al-Saad S, Al-Shibli K, Dønnem T, Andersen S, Bremnes RM, Busund L-T. High HER2 gene copy number evaluated by silver in situ hybridization (SISH) is associated with worse outcome in the female non-small cell lung cancer population. J Thorac Oncol 5:1536-1543, 2010
Florholmen J, Kristiansen MG, Steigen SE, Sørbye SW, Paulssen EJ, Kvamme JM, Konopski Z, Gutteberg T, Goll R. A rapid chemokine response of macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and the regulated on activation, normal T expressed and secreted chemokine is associated with a sustained virological response in the treatment of chronic hepatitis C. Clin Microbiol Infect. 2010 Mar 6 [Epub ahead of print].
Richardsen E, Uglehus RD, Due J, Busch C, Busund LT. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol. 2010 Jun;34(3):316-22.
Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fosså SD. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010 Oct 20;28(30):4649-57.
Norum J, Nieder C, Kondo M. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J Chemother 2010; 22: 75-82
Norum J, Elsbak TM. The ambulance service in northern Norway 20045-2008. Improved competence, more tasks, better logistics and increased costs. Int J Emerg Med 2010; 3: 69-74.
Nieder C, Norum J, Stemland JG, Dalhaug A.Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis. Oncology. 2010;78(5-6):348-55.
Rutskij R, Gaarden T, Bremnes R, Dahl O, Finset A, Fosså SD, Klepp O, Sørebø Ø, Wist E, Dahl AA. A study of coping in long-term testicular cancer survivors. Psychol Health Med 15; 146-158, 2010
Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten Ø, Amundsen T, Hjelde H, von Plessen C, Jordhøy M. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer 46; 2225-2234, 2010
Dahl CF, Haugnes HS, Bremnes R, Dahl O, Fosså SD, Klepp O, Wist E, Dahl AA. A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. J Cancer Surviv 4; 256-265, 2010
Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O. Long-term follow-up after risk adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Ann Oncol 21:1858-1863, 2010
Brydøy M, Fosså SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O; for the Norwegian Urology Cancer Group III study group. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 58: 134-141, 2010
Strand T-E, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Hornslien K, Bremnes RM, Stensvold A, Garpestad O, Norstein J. Potentially curative radiotherapy for non-small cell lung cancer in Norway – a population-based study of survival. Int J Rad Oncol Biol Phys 2010 May 6. [Epub ahead of print]
Wethal T, Haugnes HS, Kjekshus J, Småstuen MC, Ueland T, Aukrust P, Fosså SD. C- reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur J Cancer 2010, epub ahead of print.
Ervik B, Nordøy T, Asplund K. Hit by waves-living with local advanced or localized prostate cancer treated with endocrine therapy or under active surveillance. Cancer Nurs. 2010;33(5):382-9.
Risberg T and Bremnes RM. Placebo eller den magiske kraft – legekunstens beste venn? In: Kreft og alternativ medisin. Risberg T (ed.), Gyldendal Akademisk, Oslo, 2010, p 141
2009
Richardsen E, Sørbye WS, Crowe JP, Yang JL, Busund LT.Correlation of M-CSF, CSF- 1R and CD68 with malignant potential in soft tissue sarcoma. Anticancer Res 2009; 29(10): 3861-6.
Dønnem T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund L-T, Bremnes RM. VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells. Lung Cancer 63; 277-283, 2009
Andersen S, Donnem T, Al-Saad S, Al-Shibli K, Busund L-T, Bremnes RM. Angiogenic markers show high prognostic impact on survival in marginally operable non-small cell lung cancer patients treated with adjuvant radiotherapy. J Thorac Oncol 4; 463-471, 2009
Dønnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: Co-expression with VEGFR-3 and PDGF-B predicts poor survival. J Thoracic Oncol 4; 578-85, 2009
Al-Shibli K, Al-Saad S, Donnem T, Persson M, Bremnes RM, Busund L-T. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 55; 301-312, 2009
Al-Saad-S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund L-T. Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cell and stromal compartment in non-small cell lung cancer. Anticancer Res 29; 4175-4183, 2009
Richardsen E, Sørbye SW, Crowe JP, Yang JL, Busund LT. Expression of M-CSF and CSF-1R is correlated with histological grade in soft tissue tumors. Anticancer Res. 2009 Oct;29(10):3861-6.
Berg T, Kalsaas A-H, Buechner J, Busund LT. Ewing tumor/peripheral neuroectodermal tumor (ET/PNET) of the kidney with a FUS ERG fusion transcript. Cancer Genet Cytogenet. 2009 Oct;194(1):53-7.
Rørtveit G, Staff A, Schem BC, Busund LT, Nakken KO, Walstad M, Dale O, Vigen T. What does the Tidsskriftet's editorial committee do?] J Nor Med Assos 2009;129(3):175. Norwegian.
Skaali T, Fosså SD, Bremnes R, Dahl O, Haaland CF, Hauge ER, Klepp O, Oldenburg J, Wist E, Dahl AA. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology 18; 580-8, 2009
Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten Ø, Amundsen T, von Plessen C, Wang M, Sundstrøm S. A prospective phase II study: High dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 63; 88-93, 2009
Iranzo V, Almendros P, Gavila J, Blasco A, Bremnes RM, Sirera R, Camps C. Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non small cell lung cancer. Lung Cancer 63; 63-67, 2009
Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrøm H, Klepp O. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: The SWENOTECA management program. J Clin Oncol 27; 2122-8, 2009
Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S. Long term follow-up of cancer patients receiving radiotherapy for bone metastases: Results from a randomised multicentre trial. Radiother Oncol 91; 261-6, 2009
Haugnes HS, Aass N, Fosså SD, Dahl O, Brydøy M, Aasebø U, Wilsgård T, Bremnes RM. Pulmonary function in long-term testicular cancer survivors. J Clin Oncol. 27; 2779-86, 2009
Grønberg BH, Bremnes RM, Fløtten Ø, Amundsen T, Brunsvig PF, Hjelde H, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S. Phase III study by the Norwegian Lung Cancer Study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first line chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 27; 3217-24, 2009.
Gude T, Vaglum P, Anvik T, Baerheim A, Fasmer OB, Grimstad H, Hjortdahl P, Holen A, Nordøy T, Eide H. Do physicians improve their communication skills between finishing medical school and completing internship? A nationwide prospective observational cohort study. Patient Educ Couns. 2009;76(2):207-12.
Nieder C, Spanne O, Nordøy T, Dalhaug A. Treatment of brain metastases from renal cell cancer. Urol Oncol. 2009 [Epub ahead of print]
Nieder C, Bremnes RM, Andratschke NH. Prognostic scores in patients with brain metastases from non-small cell lung cancer J Thorac Oncol 4; 1337-1341, 2009
Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø, Plessen CV, Bremnes RM. Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol 48; 1019-1025, 2009
Grov EK, Fosså SD, Bremnes RM, Dahl O, Klepp O, Wist E, Dahl AA. The personality trait of neuroticism is strongly associated with long term morbidity in testicular cancer survivors. Acta Oncol 48; 842-849, 2009
Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O, Fosså SD. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682-1695, 2009
Nieder C, Norum J, Spanne O, Bilberg I, Vagstad G, Dalhaug A. Does distance to treatment centre influence the rate of palliative radiotherapy in adult cancer patients? Anticancerr Res 2009; 29: 2641-4
Norum J. Those days cooperation was poor. J Nor Med Assoc 2009; 129: 2626-2627.
Bremnes RM, Aasebø U. Svulster i luftveiene. In: Kreftsykdommer – En basisbok for helsepersonell. 3rd ed. Kåresen R, Wist E (eds). Gyldendal, Oslo. 2009, p 211-229
Lehne G, Sundby Hall K, Bremnes RM, Slørdal L. Individuelt tilpasset behandling med cytostatika.. In: Medikamentell kreftbehandling. Cytostatikaboken. Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T (eds). 7th edition. 2009, p. 91-109.
Slørdal L, Bremnes RM, Sørbye H. Antimetabolitter. In: Medikamentell kreftbehandling. Cytostatikaboken. Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T (eds). 7th edition. 2009, p. 183-196.
Sundstrøm S, Bremnes RM, von Plessen C, Brunsvig P. Lungekreft. In: Medikamentell kreftbehandling. Cytostatikaboken. Dahl O, Lehne G, Baksaas I, Kvaløy S, Christoffersen T (eds). 7th edition. 2009, p. 376-386.
Risberg T. In: Kreftsykdommer – en basisbok for helsepersonell. Eds: Rolf Kåresen, Erik Wist : 2009. 3rd ed. ISBN/EAN: 9788205384859
Molls M, Nieder C, Belka C, Norum J. Quantitative cell kill of radiotherapy and chemotherapy. In Mills M, Vaupel P, Nieder C, Snscher MS (eds). The impact of tumor biology on cancer treatment and multidisciplinary strategies. Springe Verlag Berlin Heidelberg 2009. (DOI 10.1007/978-3-540-74386-6
2008
Al-Shibli K, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T. Prognostic impact of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14; 5220-7, 2008
Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund L-T, Bremnes RM. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 3; 963-70, 2008
Al-Saad-S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund L-T. The prognostic impact of NFκB p105, vimentin, E-cadherin, and Par6 expression in epithelial and stromal compartment in non-small cell lung cancer. Br J Cancer 99; 1476-83, 2008
Richardsen E, Uglehus RD, Due J, Busch C, Busund LTB (2008), The prognostic impact of M-CSF, CSF-1R, CD68 and CD3 in prostate cancer. Histopathology 2008; 53: 30-38.
Hanssen S, Norum J. Bladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer. Anticancer Res. 2008 Sep-Oct;28(5B):2865-8.
Dalhaug A, Pawinski A, Norum J, Nieder C. Presentation and course of brain metastases from breast cancer in a paranoid-schizophrenic patient: A case report. Cases J. 2008 Sep 30;1(1):195.
Augestad KM, Vonen B, Aspevik R, Nestvold T, Ringberg U, Johnsen R, Norum J, Lindsetmo RO. Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost-effectiveness and serious clinical events. BMC Health Serv Res. 2008 Jun 25;8:137.
Nieder C, Marienhagen K, Thamm R, Astner ST, Molls M, Norum J. Prediction of very short survival in patients with brain metastases from breast cancer. Clin Oncol (R Coll Radiol). 2008 Jun;20(5):337-9. Epub 2008 Apr 18.
Norum J, Moen MA. Practice and costs of red blood cell (RBC) transfusion in an oncological unit. Anticancer Res. 2008 Jan-Feb;28(1B):459-64.
Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis. Eur J Cancer. 2008 May;44(7):963-71. Epub 2008 Mar 24.
Johansen MA, Fossen K, Norum J, Christoffersen T, Oritsland H, Haga D, Hasvold P, Bellika JG, Knarvik U, Pedersen S. The potential of digital monochrome images versus colour slides in telescreening for diabetic retinopathy. J Telemed Telecare. 2008;14(1):27-31.
Nieder C, Marienhagen K, Dalhaug A, Norum J. Have changes in systemic treatment improved survival in patients with breast cancer metastatic to the brain? J Oncol. 2008;2008:417137. Epub 2008 Sep 23.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One. 2008 Aug 26;3(8):e3062.
Anvik T, Grimstad H, Baerheim A, Bernt Fasmer O, Gude T, Hjortdahl P, Holen A, Risberg T, Vaglum P. Medical students' cognitive and affective attitudes towards learning and using communication skills--a nationwide cross-sectional study. Med Teach. 2008;30(3):272-9.
Orre IJ, Fosså SD, Murison R, Bremnes RM, Klepp O, Loge JH, Wist E, Dahl AA. Chronic fatigue in long-term survivors of testicular cancer. J Psychosom Res 64; 363-71, 2008
Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sørenson S. Irinotecan plus carboplatin is superior to oral etoposide plus carboplatin in extensive small cell lung cancer – results from a randomized phase III trial. J Clin Oncol 26; 4261-7, 2008
Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgård T, Bremnes RM. Cardiovascular morbidity and predicted mortality in testicular cancer survivors. J Cancer Surviv 2; 128-37, 2008
Helbekkmo N, Aasebø U, Sundstrøm SH, Brunsvig PF, von Plessen C, Bremnes RM. Treatment outcome in performance status 2 NSCLC patients following platinum-based combination chemotherapy within a phase III study. Lung Cancer 62; 253-260, 2008
Risberg T. In: Palliasjon Nordisk Lærebok. Ed: Stein Kaasa, 2008, 2nd ed. ISBN/EAN: 9788205351813
Nieder C, Bremnes RM. Effects of smoking cessation on hypoxia and its potential impact on radiation treatment effects in lung cancer patients. Strahlenter Onkol 184; 605-609, 2008
2007
Dønnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund L-T, Bremnes RM. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non-small cell lung cancer (NSCLC). Clin Cancer Res 13; 6649-57, 2007
Berdal M, Hege I. Appelbom, Jorunn H Eikrem, Åse Lund, Svetlana Zykova, Lill-Tove Busund, Rolf Seljelid, Trond Jenssen. Aminated β-1,3-D-glucan improves wound healing in diabetic db/db mice. Wound Rep Regen 2007;15, 825-32.
Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Svartberg J, Wilsgaard T, Bremnes RM. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18; 241-8, 2007
Helbekkmo N, Sundstrøm S, Aasebø U, Brunsvig P, von Plessen C, Bremnes RM. A randomized comparison of vinorelbine/carboplatin versus gemcitabine/carboplatin in advanced non-small cell lung cancer. Br J Cancer 97; 283-9, 2007
Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 52; 1438-47, 2007
Anvik T, Gude T, Grimstad H, Baerheim A, Fasmer OB, Hjortdahl P, Holen A, Risberg T, Vaglum P. Assessing medical students' attitudes towards learning communication skills--which components of attitudes do we measure? BMC Med Educ. 2007;7:4.
Baerheim A, Hjortdahl P, Holen A, Anvik T, Fasmer OB, Grimstad H, Gude T, Risberg T, Vaglum P. Curriculum factors influencing knowledge of communication skills among medical students. BMC Med Educ. 2007 Oct 10;7:35.
Gude T, Vaglum P, Anvik T, Baerheim A, Eide H, Fasmer OB, Graugaard P, Grimstad H, Hjortdahl P, Holen A, Nordoy T, Skirbekk H, Finset A. Observed communication skills: how do they relate to the consultation content? A nation-wide study of graduate medical students seeing a standardized patient for a first-time consultation in a general practice setting. BMC Med Educ. 2007;7:43.
Norum J, Pedersen S, Størmer J, Rumpsfeld M, Stormo A, Jamissen N, Sunde H, Ingebrigtsen T, Larsen ML. Which telemedisine services should be given priority for large scale implementation? J Telemed Telecare 2007; 13(4):185-92.
Norum J, Bergmo TS, Holdø B, Johansen MV, Vold IN, Sjaaeng EE, Jacobsen H. A teleobstetric broadband service includning ultrasound, videoconferencing and cardiotocogram. A high cost and a low volume of patients. J Telemed Telecare 2007;13(4):180-4.
Norum J, Olsen JA, Wist EA, Lønning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol 2007; 46:153-164.
Norum J. Cetuximab (Erbitux®) in the Treatment of Metastatic Colorectal Cancer: a Model-based Cost-effectiveness Analysis. J Chemother 2007; 18: 532-537.
Holtan A, Aass N, Nordøy T, Haugen DF, Kaasa S, Mohr W, Kongsgaard UE. Prevalence of pain in hospitalised cancer patients in Norway: a national survey. Palliat Med. 2007;21(1):7-13.
Dalhaug A, Pawinski A, Norum J, Nieder C. An uncommon presentation and course of metastatic malignant melanoma: a case report. J Med Case Reports. 2007 Nov 26;1:151.
2006
Bremnes RM, Sirera R, Camps C. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung cancer 51; 143-158, 2006.
Camps C, Sirera R, Bremnes RM, Blasco A, Sancho E, Bayo P, Safont MJ, Sánchez JJ, Tarón M, Rosell R. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer 50; 339-46, 2005.
Camps C, Sirera R, Bremnes RM, Garde J, Safont MJ, Blasco A, Berrocal A, Sanchez JJ, Calabuig C, Martorell M. Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications. Lung Cancer 52; 343-7, 2006.
Camps C, Sirera R, Bremnes RM, Rodenas V, Blasco A, Safont MJ, Garde J, Juarez A, Caballero C, Sanchez JJ, Tarón M, Rosell R. Quantitation in the serum of the catalytic fraction of reverse telomerase: A useful prognostic factor in advanced non-small cell lung cancer. Anticancer Res 26; 4905-10, 2006
Norum J, Jordøy MS. A university oncology department and a remote palliative care unit linked together by email and videoconferencing. J Telemed Telecare 2006; 12, 92-96
Norum J. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opionion Pharmacother 2006, 7, 1617-25.
Geisler J, Lonning PE, Krag LE, Lokkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer. 2006 Nov;42(17):2968-75.
Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Borresen-Dale AL, Lillehaug JR, Lonning PE. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. Clin Cancer Res. 2006 Oct 15;12:6000-4.
Sørlie T, Rosenvinge JH, Bremnes RM, Balteskard L, Dahl AA, Klepp O, Fosså SD. Management satisfaction in survivors of testicular cancer. Anticancer Research 26; 1463-70, 2006.
Sundstrøm S, Bremnes RM, Brunsvig P, Kaasa S. Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: which patients should be treated with short course radiotherapy. J Thorac Oncol 1; 816-24, 2006
von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrøm S, Gilleryd M, Stephens R, Vilsvik J, Aasebø U, Sørenson S. Palliative chemotherapy beyond 3 courses conveys no survival or consistent quality of life benefits in advanced non-small cell lung cancer. Br J Cancer 95; 966-73, 2006
Donnem T, Nordoy T, Ervik B, Jordoy M. Centralized inpatient palliative care units in remote areas: an obstacle to future home care? Palliat Med. 2006 Mar;20(2):116-7
Camps C, Iranzo V, Bremnes RM, Sirera R. Anorexia-cachexia syndrome in cancer: Implications of the ubiquitin-proteasome pathway. Support Care Cancer 14; 1173-83, 2006.
Aass N, Bjordal K, Tveit KM, Nordøy T. [Tumour-modifying therapy]. Tidsskr Nor Laegeforen. 2006;126(5):628-32. Review.
Nordøy T, Thoresen L, Kvikstad A, Svensen R. [Treatment with nutrition and fluids in patients with non-curable cancer] J Nor Med Assoc 2006;126(5):624-7. Review.
Bremnes RM, Von Plessen C, Sundstrøm S. Lungekreft – mer aktuelt enn noen gang. J Nor Med Assos 126: 1940, 2006.
Johansen K, Lønning PE, Naume B, Norum J, Olsen JA, Wist E. Ny medikamentell behandling av brystkreft. Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft. Nasjonalt kunnskapssenter for helsetjenesten. Rapport nr. 2, 2006.
Johansen K, Wisløff T, Kristiansen IS, Lønning PE, Naume B, Norum J, Norderhaug IN, Olsen JA, Wist E. Ny medikamentell behandling av brystkreft. Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft. En helseøkonomisk analyse. Nasjonalt kunnskapssenter for helsetjenesten. Rapport nr. 18, 2006.
Norum J, Pedersen S, Størmer J, Rumpsfeld M, Stormo A, Jamissen N, Sunde H, Ingebrigtsen T, Larsen ML. Hvilke utprøvde og egnede telemedisinske tjenesten bør prioriteres for storskala implementering. Helse-Nord rapport 2006
2005
Bremnes RM, Sirera R, Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up. Lung Cancer 49; 1-12, 2005.
Bremnes RM, Aasebø U. Svulster i luftveiene. In: Kreftsykdommer – en basisbok for helsepersonell. 2nd ed. Kåresen R, Wist E (eds). Gyldendal, Oslo. 2005, p 200.
Busund LT, Richardsen E, Busund R, Ukkonen T, Bjørnsen T, Busch C, Stalsberg H.A significant expression of IGFBP2 in infiltrating breast cancer compared to carcinoma in situ and benign lesions. J Clin Pathol. 2005;58(4):361-366
Brandal P, Busund LT, Heim S. Genomic Abnormalities in Juxtaglomerular Cell Tumors. Cancer. 2005, 104:504-10.
Al-Shibli KI, Mohammed HA, Mikalsen KS. Sentinel lymph nodes and breast carcinoma: analysis of 70 cases by frozen section. Ann Saudi Med. 2005 Mar-Apr;25(2):111-4.
Thorsen L, Nystad W, Stigum H, Dahl O, Klepp O, Bremnes RM, Wist E, Fosså SD. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer 13: 637-46, 2005.
Dahl AA, Haaland CF, Mykletun A, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 23: 2389-95, 2005.
Holtedahl K, Norum J, Anvik T, Richardsen E. Do cancer patients benefit from short- term contact with a general practitioner following cancer treatment? A randomised, controlled study. Support Care Cancer. 2005;13(11):949-956
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S. Second-line chemotherapy in recurrent small-cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 48; 251-61, 2005.
Mykletun A, Dahl AA, Haaland CF, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 23; 3061-8, 2005.
Sundstrøm S, Bremnes RM, Aasebø U, Brunsvig P, Johannessen DC, Klepp O, Fayers P, Kaasa S. Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol 75; 141-8, 2005
Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgård T, Bremnes RM. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23; 4980-90, 2005.
Kildahl-Andersen A, Erke MG, Sagstuen H, Bremnes RM. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration. Acta Oncol 44; 537-44, 2005.
Brydøy M, Fosså SD, Klepp O, Wist E, Bremnes R, Dahl O. Post-treatment paternity in testicular cancer survivors: varies according to treatment. J Natl Cancer Inst 97; 1580-8, 2005.
Camps C, Caballero C, Blasco A, Safont MJ, Berrocal A, Garde J, Juarez A, Sirera R, Bremnes RM. Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer: Efficacy and tolerability. Anticancer Res 25; 4611-4, 2005.
T. Risberg. Køpinikade? Tidsskr Nor Lægeforen 2005; 125: 467-68.
Gude T, Baerheim A, Holen A, Anvik T, Finset A, Grimstad H, Hjortdahl P, Risberg T, Vaglum P. Comparing self-reported communication skills of medical students in traditional and integrated curricula: A nationwide study. Patient Educ Couns. 2005 Sep;58(3):271-8
Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005; 16: 909-919.
Norum J, Bruland Ø, Spanne O, Bergmo T, Green T. Olsen DR, Olsen JH, Sjåeng EE, Burkow T. Telemedicine in radiotherapy: a study exploring remote treatment planning, supervision and economics. J Telemed Telecare 2005; 11: 245-250.
Rumpsfeld M, Arild E, Norum J, Breivik E. Telemedicine in haemodialysis; a univeristy department and two remote satellites linked together as one common workplace. J Telemed Telecare 2005; 11: 251-255.
Norum J, Holtmon M. Adjuvant fluorouracil, epirubicin and cyclophosphamide (FEC) in early breast cancer. Is it cost-effective? Acta Oncol 2005; 44: 735-741.
Norum J, Bergli E. Norwegian surgical and medical oncologists’ use of the Internet. A new source for professional updating. Anticancer Re 2005; 25: 395-98.
Holtedahl K, Norum J, Anvik T, Richardsen E. Do cancer patients benefit from short-term contact with a general practitioner following cancer treatment? A randomised controlled study. Supp Care Cancer 2005, 13: 949-956
Von Plessen C (Ed), Bremnes RM, Aasebø U, Sundstrøm. Lungekreft. Diagnostikk og behandling. 2. utgave 2005. www.onkologiskforum.org/lunge/handlingsplan.html
